Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AKRO | Akero Therapeutics, Inc.

IndexRUT P/E- EPS (ttm)-2.56 Insider Own2.10% Shs Outstand51.87M Perf Week-4.49%
Market Cap2.62B Forward P/E- EPS next Y-3.35 Insider Trans27.13% Shs Float48.18M Perf Month1.94%
Income-115.50M PEG- EPS next Q-0.69 Inst Own87.71% Short Float / Ratio13.14% / 8.35 Perf Quarter-6.83%
Sales- P/S- EPS this Y0.70% Inst Trans26.54% Short Interest6.33M Perf Half Y27.76%
Book/sh11.88 P/B4.08 EPS next Y-21.80% ROA-26.40% Target Price68.29 Perf Year84.47%
Cash/sh11.84 P/C4.09 EPS next 5Y-14.60% ROE-29.00% 52W Range25.21 - 58.38 Perf YTD-11.57%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-16.99% Beta-0.92
Dividend %- Quick Ratio29.80 Sales past 5Y- Gross Margin- 52W Low92.23% ATR1.96
Employees44 Current Ratio29.80 Sales Q/Q- Oper. Margin- RSI (14)47.30 Volatility4.74% 3.81%
OptionableYes Debt/Eq0.04 EPS Q/Q22.60% Profit Margin- Rel Volume1.30 Prev Close48.60
ShortableYes LT Debt/Eq0.04 EarningsAug 11 BMO Payout- Avg Volume758.74K Price48.46
Recom1.70 SMA20-2.56% SMA503.80% SMA2006.26% Volume986,265 Change-0.29%
Date Action Analyst Rating Change Price Target Change
Sep-19-23Initiated Cantor Fitzgerald Overweight $69
Aug-28-23Initiated UBS Buy $83
Jan-27-23Upgrade Morgan Stanley Equal-Weight → Overweight $40 → $65
Sep-14-22Upgrade Evercore ISI In-line → Outperform $10 → $50
Oct-19-21Downgrade Morgan Stanley Overweight → Equal-Weight $27
Sep-10-21Initiated BofA Securities Buy $40
Feb-26-21Initiated Guggenheim Buy $54
Sep-10-20Initiated Morgan Stanley Overweight $70
Jul-20-20Reiterated H.C. Wainwright Buy $45 → $62
Jul-07-20Initiated Chardan Capital Markets Buy $79
Jul-15-19Initiated Evercore ISI Outperform $35
Sep-14-23 07:56AM
Aug-31-23 07:00AM
Aug-28-23 07:00AM
Aug-11-23 06:00AM
Jul-11-23 09:02AM
09:32AM Loading…
Jul-10-23 09:32AM
09:29AM
08:58AM
Jul-07-23 08:00AM
07:46AM
Jul-03-23 11:20AM
10:25AM
Jul-01-23 09:00AM
Jun-29-23 10:04AM
09:59AM
09:18AM Loading…
09:18AM
Jun-28-23 10:53AM
Jun-27-23 01:47PM
Jun-26-23 11:23AM
11:15AM
10:36AM
08:50AM
08:21AM
06:41AM
Jun-23-23 10:50AM
09:15AM
07:00AM
Jun-22-23 09:18AM
Jun-21-23 03:21PM
10:46AM
08:54AM Loading…
Jun-20-23 08:54AM
Jun-19-23 10:28AM
10:18AM
Jun-16-23 10:26AM
08:39AM
Jun-15-23 09:43AM
08:18AM
Jun-14-23 12:17PM
11:48AM
09:26AM
Jun-13-23 10:14AM
09:40AM
09:18AM
Jun-12-23 10:00AM
09:48AM
Jun-08-23 11:49AM
11:20AM
Jun-07-23 12:31PM
08:50AM
Jun-06-23 01:13PM
12:13PM
11:14AM
Jun-05-23 12:43PM
11:40AM
10:22AM
07:39AM
07:14AM
07:00AM
Jun-02-23 11:36AM
07:12AM
Jun-01-23 04:05PM
May-31-23 10:46AM
08:00AM
May-30-23 10:56AM
May-29-23 07:48AM
May-26-23 10:51AM
May-24-23 08:14AM
May-23-23 09:55AM
May-17-23 01:59PM
May-16-23 06:53PM
06:33AM
May-15-23 07:00AM
May-10-23 08:50AM
May-04-23 09:21AM
06:26AM
Apr-18-23 09:55AM
Mar-29-23 04:01PM
Mar-22-23 04:09PM
09:14AM
Mar-17-23 07:00AM
Jan-10-23 08:00AM
Jan-04-23 08:00AM
Dec-22-22 07:44AM
Dec-21-22 04:01PM
Dec-20-22 11:15AM
Dec-08-22 07:00AM
Nov-13-22 07:46AM
Nov-10-22 04:05PM
Nov-07-22 09:40AM
07:30AM
Nov-04-22 07:00AM
Nov-03-22 06:53PM
Nov-02-22 11:14AM
Oct-21-22 12:27PM
12:06PM
09:40AM
Oct-11-22 08:56PM
04:01PM
Oct-05-22 09:40AM
Sep-23-22 06:35PM
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Graham G. WalmsleyDirectorSep 19Buy26.00400,00010,400,000400,000May 23 09:55 PM
Cheng AndrewPresident and CEOSep 01Option Exercise6.3625,000159,000487,680Sep 18 06:48 PM
Cheng AndrewPresident and CEOSep 01Sale49.7725,0001,244,248462,680Sep 18 06:48 PM
Cheng AndrewPresident and CEOAug 30Option Exercise0.6115,0009,225462,680Aug 30 07:04 PM
Yale CatrionaChief Development OfficerAug 28Option Exercise6.365,74536,53852,372Aug 30 07:04 PM
Yale CatrionaChief Development OfficerAug 28Sale49.995,745287,19146,627Aug 30 07:04 PM
Graham G. WalmsleyDirectorAug 08Buy42.0625,0001,051,475600,000Aug 10 04:46 PM
Cheng AndrewPresident and CEOAug 01Option Exercise6.3625,000159,000472,680Aug 03 04:13 PM
Graham G. WalmsleyDirectorAug 01Buy43.2625,0001,081,525575,000Aug 01 07:52 PM
Cheng AndrewPresident and CEOAug 01Sale43.1525,0001,078,867447,680Aug 03 04:13 PM
Graham G. WalmsleyDirectorJul 28Buy42.6930,0001,280,709550,000Aug 01 07:52 PM
Cheng AndrewPresident and CEOJul 03Option Exercise6.3625,000159,000472,680Jul 06 08:44 PM
Cheng AndrewPresident and CEOJul 03Sale44.8825,0001,122,041447,680Jul 06 08:44 PM
Cheng AndrewPresident and CEOJun 27Option Exercise0.6140,00024,600447,680Jun 27 07:12 PM
Yale CatrionaChief Development OfficerJun 23Sale50.7611,000558,36046,627Jun 23 08:06 PM
Yale CatrionaChief Development OfficerJun 22Sale52.1811,000573,93557,627Jun 23 08:06 PM
Yale CatrionaChief Development OfficerJun 21Sale52.2611,349593,09568,627Jun 23 08:06 PM
White William RichardChief Financial OfficerJun 20Option Exercise7.0117,500122,65839,877Jun 22 05:20 PM
White William RichardChief Financial OfficerJun 20Sale55.0020,7771,142,73519,100Jun 22 05:20 PM
Heyman Tomas J.DirectorJun 16Option Exercise25.0426,000651,04026,000Jun 21 05:54 PM
Henderson JaneDirectorJun 16Option Exercise7.0140,000280,40040,000Jun 21 05:47 PM
Rolph TimothyChief Scientific OfficerJun 16Option Exercise0.6140,00024,400229,420Jun 21 05:46 PM
Rolph TimothyChief Scientific OfficerJun 16Sale54.7878,2004,284,066151,220Jun 21 05:46 PM
Henderson JaneDirectorJun 16Sale54.1740,0002,166,6850Jun 21 05:47 PM
Heyman Tomas J.DirectorJun 16Sale54.6726,0001,421,5290Jun 21 05:54 PM
Cheng AndrewPresident & CEOJun 13Sale55.161,61388,973407,680Jun 15 09:38 PM
White William RichardChief Financial OfficerJun 13Sale55.1660633,42722,377Jun 15 09:41 PM
Yale CatrionaChief Development OfficerJun 13Sale55.1659132,60079,976Jun 15 09:29 PM
Young JonathanChief Operating OfficerJun 13Sale55.1653829,676183,739Jun 15 09:35 PM
Rolph TimothyChief Scientific OfficerJun 13Sale55.1650928,076189,420Jun 15 09:35 PM
Cheng AndrewPresident and CEOJun 01Option Exercise1.4625,00036,459434,293Jun 05 06:23 PM
Cheng AndrewPresident and CEOJun 01Sale45.1025,0001,127,430409,293Jun 05 06:23 PM
Graham G. WalmsleyDirectorMay 19Buy42.00120,0005,040,000520,000May 23 09:55 PM
Cheng AndrewPresident & CEOMay 01Option Exercise0.6125,00015,375434,293May 03 08:28 PM
Cheng AndrewPresident & CEOMay 01Sale45.0725,0001,126,860409,293May 03 08:28 PM
Cheng AndrewPresident & CEOApr 18Option Exercise0.6140,00024,600409,293May 03 08:28 PM
Cheng AndrewPresident & CEOApr 03Option Exercise0.6125,00015,375394,293Apr 05 04:55 PM
Cheng AndrewPresident & CEOApr 03Sale37.9425,000948,576369,293Apr 05 04:55 PM
Cheng AndrewPresident & CEOMar 01Option Exercise0.6125,00015,375395,999Mar 03 04:21 PM
Cheng AndrewPresident & CEOMar 01Sale46.6525,0001,166,338370,999Mar 03 04:21 PM
Cheng AndrewPresident & CEOFeb 01Option Exercise0.6125,00015,375395,999Feb 03 05:25 PM
Cheng AndrewPresident & CEOFeb 01Sale49.0625,0001,226,395370,999Feb 03 05:25 PM
Yale CatrionaChief Development OfficerJan 13Sale50.535,000252,65181,268Jan 18 05:30 PM
Cheng AndrewPresident & CEOJan 03Option Exercise0.6125,00015,375395,999Jan 05 06:46 PM
Young JonathanChief Operating OfficerJan 03Option Exercise0.618,7775,398193,688Jan 05 05:56 PM
Cheng AndrewPresident & CEOJan 03Sale51.2725,0001,281,751370,999Jan 05 06:46 PM
Young JonathanChief Operating OfficerJan 03Sale54.648,777479,560184,911Jan 05 05:56 PM
Rolph TimothyChief Scientific OfficerDec 29Option Exercise28.357,816221,584210,848Dec 30 04:26 PM
Rolph TimothyChief Scientific OfficerDec 29Sale51.0520,3161,037,119190,532Dec 30 04:26 PM
Rolph TimothyChief Scientific OfficerDec 28Option Exercise28.351,70048,195204,732Dec 30 04:26 PM
White William RichardChief Financial OfficerDec 28Option Exercise7.019997,00224,623Dec 29 05:41 PM
Rolph TimothyChief Scientific OfficerDec 28Sale50.001,70085,006203,032Dec 30 04:26 PM
White William RichardChief Financial OfficerDec 28Sale49.7699949,71423,624Dec 29 05:41 PM
White William RichardChief Financial OfficerDec 27Option Exercise7.0119,001133,17842,625Dec 29 05:41 PM
Young JonathanChief Operating OfficerDec 27Option Exercise6.0312,50075,352194,949Dec 28 06:30 PM
White William RichardChief Financial OfficerDec 27Sale49.7719,001945,60923,624Dec 29 05:41 PM
Young JonathanChief Operating OfficerDec 27Sale49.5712,500619,609182,449Dec 28 06:30 PM
Cheng AndrewPresident & CEODec 16Option Exercise0.618,5005,228370,999Dec 20 07:46 PM
Yale CatrionaChief Development OfficerDec 12Sale43.235,000216,13786,268Dec 13 08:24 PM
Cheng AndrewPresident & CEODec 01Option Exercise0.6110,0006,150320,148Dec 02 05:52 PM
Skorpios TrustFormer 10% ownerDec 01Sale43.501,636,00071,166,0003,271,829Dec 05 04:36 PM
Cheng AndrewPresident & CEODec 01Sale46.0710,000460,700310,148Dec 02 05:52 PM
Harrison Seth LoringDirectorNov 30Sale46.9412,030564,673148,063Dec 02 05:48 PM
Harrison Seth LoringDirectorNov 30Sale46.9411,101521,067136,301Dec 02 05:48 PM
Rolph TimothyChief Scientific OfficerNov 16Sale45.473,947179,464183,837Nov 16 07:15 PM
Rolph TimothyChief Scientific OfficerNov 15Sale45.043,138141,343187,784Nov 16 07:15 PM
Yale CatrionaChief Development OfficerNov 10Sale39.425,000197,10572,073Nov 14 05:26 PM
Cheng AndrewPresident & CEONov 01Option Exercise0.6110,0006,150320,148Nov 02 09:52 PM
Cheng AndrewPresident & CEONov 01Sale43.4210,000434,183310,148Nov 02 09:52 PM
Harrison Seth LoringDirectorOct 28Sale40.3122,965925,738160,093Nov 01 05:38 PM
Harrison Seth LoringDirectorOct 28Sale40.3121,138852,091147,402Nov 01 05:38 PM
Harrison Seth LoringDirectorOct 27Sale41.5372,1722,997,575183,058Oct 27 09:50 PM
Harrison Seth LoringDirectorOct 27Sale41.5366,4262,758,920168,540Oct 27 09:50 PM
Harrison Seth LoringDirectorOct 26Sale43.7571,5833,131,402255,230Oct 27 09:50 PM
Harrison Seth LoringDirectorOct 26Sale43.7565,8852,882,142234,966Oct 27 09:50 PM
Rolph TimothyChief Scientific OfficerOct 26Sale45.034,762214,433190,922Oct 27 09:27 PM
Rolph TimothyChief Scientific OfficerOct 25Option Exercise10.3110,000103,116206,337Oct 27 09:27 PM
Young JonathanChief Operating OfficerOct 25Option Exercise6.3612,50079,500175,754Oct 27 09:25 PM
Young JonathanChief Operating OfficerOct 25Sale44.7212,500558,944163,254Oct 27 09:25 PM
Rolph TimothyChief Scientific OfficerOct 25Sale45.0910,653480,349195,684Oct 27 09:27 PM
Harrison Seth LoringDirectorOct 25Sale44.924,906220,359326,813Oct 27 09:50 PM
Harrison Seth LoringDirectorOct 25Sale44.924,515202,797300,851Oct 27 09:50 PM
White William RichardChief Financial OfficerOct 13Option Exercise7.0120,000140,18024,429Oct 17 05:40 PM
White William RichardChief Financial OfficerOct 13Sale39.8220,000796,4004,429Oct 17 05:40 PM
Yale CatrionaChief Development OfficerOct 10Sale37.995,000189,95077,073Oct 12 04:59 PM
Rolph TimothyChief Scientific OfficerOct 06Option Exercise21.0910,000210,900208,837Oct 07 06:00 PM
Rolph TimothyChief Scientific OfficerOct 06Sale39.2922,500884,025186,337Oct 07 06:00 PM
Cheng AndrewPresident & CEOOct 03Option Exercise0.6110,0006,150320,148Oct 05 08:55 AM
Cheng AndrewPresident & CEOOct 03Sale33.2310,000332,278310,148Oct 05 08:55 AM
Rolph TimothyChief Scientific OfficerSep 30Option Exercise16.4320,000328,589243,837Oct 04 08:57 PM
Rolph TimothyChief Scientific OfficerSep 30Sale32.7245,0001,472,400198,837Oct 04 08:57 PM